Invokana® (canagliflozin) is a subtype 2 sodium-glucose transport inhibitor marketed by Janssen, a subsidiary of Johnson & Johnson. Invokana works to lower the body’s blood sugar levels by stopping the kidneys from reabsorbing blood glucose. Instead of the blood glucose staying in the body, it is removed with the body’s urine.
INVOKANA + TYPE 2 DIABETES
Type 2 diabetes is a condition that affects the body’s ability to break down sugar (glucose) as an energy source. If you or a loved one used the type 2 diabetes medication Invokana, you might be eligible for financial compensation. Some Invokana users have required amputation of the leg, foot or toe after using the drug. Others have developed diabetic ketoacidosis or suffered other side effects such as severe kidney infection, heart attack or stroke after taking Invokana. Invokana is an SGLT2 inhibitor, which is a type of medication that works by lowering blood glucose levels. It does this by encouraging higher amounts of sugar to be released through urine. Though the medication does help control blood sugar levels, it triggers a number of other side effects, many of which are severe.
Some Invokana users experienced cardiovascular issues including heart attacks and strokes, as well as diabetic ketoacidosis and kidney health issues. Final results from two clinical studies, CANVAS and CANVAS-R have shown that use of Invokana may double the risk for limb amputation and have prompted the FDA to release a black box warning about the risk. For some, the use of Invokana triggered side effects so severe they needed hospitalization. Others suffered permanent disability. In response to these devastating medical emergencies, many Invokana users have opted to take legal action against the makers of the drug. Both Janssen Pharmaceuticals and its parent company, Johnson & Johnson, allegedly failed to warn consumers and doctors about the risks linked to their drug.